HomeCompareORINF vs DGRO

ORINF vs DGRO: Dividend Comparison 2026

ORINF yields 2.71% · DGRO yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DGRO wins by $5.0K in total portfolio value
10 years
ORINF
ORINF
● Live price
2.71%
Share price
$78.95
Annual div
$2.14
5Y div CAGR
9.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.6K
Annual income
$871.03
Full ORINF calculator →
DGRO
iShares Core Dividend Growth ETF
● Live price
2.13%
Share price
$68.98
Annual div
$1.47
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$31.6K
Annual income
$239.96
Full DGRO calculator →

Portfolio growth — ORINF vs DGRO

📍 DGRO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodORINFDGRO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ORINF + DGRO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ORINF pays
DGRO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ORINF
Annual income on $10K today (after 15% tax)
$230.40/yr
After 10yr DRIP, annual income (after tax)
$740.38/yr
DGRO
Annual income on $10K today (after 15% tax)
$181.24/yr
After 10yr DRIP, annual income (after tax)
$203.97/yr
At 15% tax rate, ORINF beats the other by $536.41/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ORINF + DGRO for your $10,000?

ORINF: 50%DGRO: 50%
100% DGRO50/50100% ORINF
Portfolio after 10yr
$29.1K
Annual income
$555.50/yr
Blended yield
1.91%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ORINF buys
0
DGRO buys
0
No recent congressional trades found for ORINF or DGRO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricORINFDGRO
Forward yield2.71%2.13%
Annual dividend / share$2.14$1.47
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR9.4%0%
Portfolio after 10y$26.6K$31.6K
Annual income after 10y$871.03$239.96
Total dividends collected$5.4K$2.3K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: ORINF vs DGRO ($10,000, DRIP)

YearORINF PortfolioORINF Income/yrDGRO PortfolioDGRO Income/yrGap
1← crossover$10,997$296.54$11,293$213.22$296.00DGRO
2$12,100$333.40$12,730$217.32$630.00DGRO
3$13,322$375.08$14,326$221.10$1.0KDGRO
4$14,676$422.22$16,098$224.56$1.4KDGRO
5$16,179$475.59$18,064$227.74$1.9KDGRO
6$17,848$536.06$20,246$230.65$2.4KDGRO
7$19,702$604.60$22,666$233.30$3.0KDGRO
8$21,764$682.38$25,349$235.73$3.6KDGRO
9$24,058$770.69$28,325$237.94$4.3KDGRO
10$26,613$871.03$31,624$239.96$5.0KDGRO

ORINF vs DGRO: Complete Analysis 2026

ORINFStock

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer, as well as Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. The company also offers veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; and APIs for generic and proprietary drugs, as well as provides contract manufacturing services. In addition, it markets and sells veterinary drugs manufactured by other international companies. The company serves various healthcare service providers and professionals, such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories, as well as consumers with pets. Orion Oyj has partnership with Propeller Health to connect the Easyhaler(R) product portfolio for the treatment of asthma and COPD; and a research collaboration and license agreement with Alligator Bioscience AB (publ) to discover and develop new bispecific antibody cancer therapeutics. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.

Full ORINF Calculator →

DGROETF

The iShares Core Dividend Growth ETF seeks to track the investment results of an index composed of U.S. equities with a history of consistently growing dividends.

Full DGRO Calculator →
📬

Get this ORINF vs DGRO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ORINF vs SCHDORINF vs JEPIORINF vs OORINF vs KOORINF vs MAINORINF vs VIGORINF vs NOBLORINF vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.